Litcius/Paper detail

Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)

Anna Mele, Eleonora Del Prete, Clara De Risi, Stefania Citiso, Giuseppina Greco, Antonietta Falcone, Grazia Sanpaolo, Giuseppe Mele, Angela Giannotta, Carolina Vergine, Giovanni Reddiconto, Giulia Palazzo, Sabrina Sabatelli, Candida Germano, R. Miccolis, Paola Curci, Gaetano Palumbo, Massimo Offidani, Rita Rizzi, Nicola Cascavilla, Domenico Pastore, Nicola Di Renzo, Patrizio Mazza, Giuseppe Tarantini, Attilio Guarini, Silvana Capalbo, Giorgina Specchia, Antonino Greco, Rosa De Francesco, Silvia Sibilla, Lorenzo Tonialini, Maria Rosaria Morciano, Vincenzo Pavone

2020Annals of Hematology23 citationsDOI

Topics & Concepts

LenalidomideCarfilzomibMedicineInternal medicineMultiple myelomaDexamethasoneRefractory (planetary science)Salvage therapyOncologyAdverse effectHematologyDiscontinuationSurgeryChemotherapyAstrobiologyPhysicsMultiple Myeloma Research and TreatmentsResearch on Leishmaniasis StudiesAmyloidosis: Diagnosis, Treatment, Outcomes
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP) | Litcius